| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PRST; IPCA6; IPCA-2; IPCA-6; IPCA-8; PCANAP2; PCANAP6; PCANAP8 |
| Entrez GeneID | 85414 |
| clone | 3F2B5 |
| WB Predicted band size | 59 kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human SLC45A3 (AA: 354-553) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于SLC45A3抗体的3篇参考文献的简要信息：
1. **文献名称**: "SLC45A3-ELK4 fusion gene promotes prostate cancer progression by enhancing cell survival and invasion"
**作者**: Chen H, et al.
**摘要**: 该研究利用SLC45A3抗体检测前列腺癌组织中的SLC45A3蛋白表达，发现其与ELK4基因的融合导致蛋白异常定位，促进肿瘤侵袭和存活。
2. **文献名称**: "Prostate-specific membrane antigen (PSMA) and SLC45A3 as biomarkers for prostate cancer diagnosis"
**作者**: Wright GL, et al.
**摘要**: 通过免疫组化(使用SLC45A3抗体)分析前列腺癌样本，发现SLC45A3与PSMA联合检测可提高早期前列腺癌的诊断特异性。
3. **文献名称**: "Characterization of monoclonal antibodies against SLC45A3 for immunohistochemical analysis in prostate cancer"
**作者**: Sasaki T, et al.
**摘要**: 研究开发并验证了针对SLC45A3的单克隆抗体，证实其在石蜡包埋组织中的有效性，并发现SLC45A3高表达与肿瘤转移相关。
(注：以上文献信息为示例，实际文献需通过PubMed或学术数据库检索核实。)
The SLC45A3 antibody targets the solute carrier family 45 member 3 (SLC45A3), a transmembrane protein implicated in melanin synthesis and cellular transport processes. SLC45A3. also known as prostein, is encoded by the SLC45A3 gene located on chromosome 1q32.1. It belongs to the SLC45 transporter family, which shares structural similarities with plant sucrose transporters. While its exact physiological role remains under investigation, SLC45A3 is highly expressed in prostate epithelial cells and has been linked to prostate cancer progression. Notably, SLC45A3-ERG gene fusions, resulting from chromosomal translocations, are recurrent events in prostate cancer and may drive oncogenesis.
Antibodies against SLC45A3 are widely used in research to study protein expression, localization, and regulatory mechanisms in normal and diseased tissues. They are employed in techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to assess SLC45A3's tissue-specific distribution and potential as a diagnostic or prognostic biomarker. In prostate cancer research, these antibodies help detect SLC45A3 overexpression or fusion protein products. Specificity validation, including knockdown/knockout controls, is critical due to homology with other SLC45 family members. Commercial antibodies are typically raised against peptide sequences within the N-terminal or central regions of the protein. Recent studies also explore its role in other cancers, such as melanoma, emphasizing its broader relevance in oncology and cellular transport biology.
×
